NCT03452228

Safety and Efficacy Following Repeat-Dose of Evinacumab (Anti-ANGPTL3) in Patients With Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis

A Phase 2, Randomized, Placebo-Controlled Study of Safety and Efficacy, Following Repeat-Dose Administration of Evinacumab (Anti-ANGPTL3) in Patients With Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 52 (actual)
• Sponsor: Regeneron Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The primary objective is to determine the change in Triglyceride (TG) levels following 12 weeks of repeated Intravenous (IV) doses of evinacumab.

Conditions

• Severe Hypertriglyceridemia (sHTG)

Interventions

Type	Name	Description
DRUG	evinacumab	Administered by Intravenous (IV)
DRUG	Placebo	Administered by Intravenous (IV)

Timeline

• Start date: 2018-06-07
• Primary completion: 2019-12-17
• Completion: 2020-07-23
• First posted: 2018-03-02
• Last updated: 2023-02-16
• Results posted: 2023-02-16

Locations

17 sites across 4 countries: United States, Canada, Italy, United Kingdom

Regulatory

• FDA-regulated drug study